Effects of elexacaftor / tezacaftor / ivacaftor triple combination therapy on glycaemic control and body composition in patients with cystic fibrosis-related diabetes
Study context
- Population
- Cystic fibrosis (CF) patients with CF-related diabetes requiring insulin therapy
- Participants
- 24 patients
- Exposure
- Before vs after 6 months of elexacaftor + tezacaftor + ivacaftor (ETI)
- ETIn = 24
- Outcome
- Effectiveness of ETI on glucose metabolism, glucose variability and body composition
- Follow-up
- Six months
Main finding
As reported in the abstract
HbA1c median change
−0.5
P = 0.029
CV median change
−6.3
P = 0.008
Observational data: associations, not effects.
Further findings
Percent fat mass · treatment period
- Median increase in % fat mass
- 3% (p = 0.029)
Original publication
Effects of elexacaftor / tezacaftor / ivacaftor triple combination therapy on glycaemic control and body composition in patients with cystic fibrosis-related diabetes. Diabetes Metab. Published 1 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →